Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 00:39, 20 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit		Latest revision as of 17:10, 15 January 2025 edit undoFswitzer4 (talk | contribs)Extended confirmed users10,990 editsm Added UNII ID
(28 intermediate revisions by 19 users not shown)
Line 1:		Line 1:
			{{Short description|Chemical compound}}
	{{drugbox
			{{Drugbox
⚫	| verifiedrevid = 375358437
			| Verifiedfields = changed
⚫	| IUPAC_name = (2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)pentan-1,5-dioic acid
			| Watchedfields = changed
	| image = LY-307,452_structure.png
		⚫	| verifiedrevid = 424946645
	| width = 180
		⚫	| IUPAC_name = (2''S'',4''S'')-2-amino-4-(4,4-diphenylbut-1-yl)pentan-1,5-dioic acid
⚫	| CAS_number =
			| image = LY-307,452.svg
⚫	| ATC_prefix =
⚫	| ATC_suffix =
⚫	| PubChem = 6324634
⚫	| DrugBank =
⚫	| C=21|H=25|N=1|O=4
	| molecular_weight = 355.428 g/mol
⚫	| smiles = C1=CC=C(C=C1)C(CCC(C(C(=O)O)N)C(=O)O)C2=CC=CC=C2
⚫	| bioavailability =
⚫	| protein_bound =
⚫	| metabolism =
⚫	| elimination_half-life =
⚫	| excretion =
⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	| pregnancy_US = <!-- A / B / C / D / X -->
⚫	| pregnancy_category=
⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫	| legal_status =
⚫	| routes_of_administration =
⚫	}}
			<!--Clinical data-->
⚫	'''LY-307,452''' is a drug used in neuroscience research, which was among the first compounds found that acts as a selective antagonist for the group II metabotropic glutamate receptors (]),<ref name="pmid8632404">{{cite journal |author=Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD |title=(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase |journal=Journal of Medicinal Chemistry |volume=39 |issue=4 |pages=814–6 |year=1996 |month=February |pmid=8632404 |doi=10.1021/jm9508144 |url=}}</ref> and was useful in early studies of this receptor family,<ref name="pmid10516668">{{cite journal |author=Li XC, Beart PM, Monn JA, Jones NM, Widdop RE |title=Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats |journal=British Journal of Pharmacology |volume=128 |issue=3 |pages=823–9 |year=1999 |month=October |pmid=10516668 |pmc=1571690 |doi=10.1038/sj.bjp.0702850 |url=}}</ref><ref name="pmid11698530">{{cite journal |author=Sung KW, Choi S, Lovinger DM |title=Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses |journal=Journal of Neurophysiology |volume=86 |issue=5 |pages=2405–12 |year=2001 |month=November |pmid=11698530 |doi= |url=}}</ref> although it has largely been replaced by newer drugs such as ].
			| tradename =
		⚫	| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
		⚫	| pregnancy_US = <!-- A / B / C / D / X -->
		⚫	| pregnancy_category =
		⚫	| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
		⚫	| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
		⚫	| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
		⚫	| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
		⚫	| legal_status =
		⚫	| routes_of_administration =
			<!--Pharmacokinetic data-->
		⚫	| bioavailability =
		⚫	| protein_bound =
		⚫	| metabolism =
		⚫	| elimination_half-life =
		⚫	| excretion =
			<!--Identifiers-->
			| IUPHAR_ligand = 3350
		⚫	| CAS_number = 174393-13-6
			| UNII_Ref = {{fdacite|correct|FDA}}
			| UNII = ZU8PFA9K8G
		⚫	| ATC_prefix =
		⚫	| ATC_suffix =
		⚫	| PubChem = 6324634
		⚫	| DrugBank =
			| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
			| ChemSpiderID = 4884363
			<!--Chemical data-->
		⚫	| C=21 | H=25 | N=1 | O=4
		⚫	| smiles = C1=CC=C(C=C1)C(CCC(C(C(=O)O)N)C(=O)O)C2=CC=CC=C2
			| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChI = 1S/C21H25NO4/c22-19(21(25)26)14-17(20(23)24)12-7-13-18(15-8-3-1-4-9-15)16-10-5-2-6-11-16/h1-6,8-11,17-19H,7,12-14,22H2,(H,23,24)(H,25,26)/t17-,19-/m0/s1
			| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
			| StdInChIKey = DWLOVDOPFJPWNE-HKUYNNGSSA-N
		⚫	}}
		⚫	'''LY-307,452''' is a drug used in neuroscience research, which was among the first compounds found that acts as a selective antagonist for the group II metabotropic glutamate receptors (]),<ref name="pmid8632404">{{cite journal |vauthors=Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD |title=(2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)-pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase |journal=Journal of Medicinal Chemistry |volume=39 |issue=4 |pages=814–6 |date=February 1996 |pmid=8632404 |doi=10.1021/jm9508144 }}</ref> and was useful in early studies of this receptor family,<ref name="pmid10516668">{{cite journal |vauthors=Li XC, Beart PM, Monn JA, Jones NM, Widdop RE |title=Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats |journal=] |volume=128 |issue=3 |pages=823–9 |date=October 1999 |pmid=10516668 |pmc=1571690 |doi=10.1038/sj.bjp.0702850 }}</ref><ref name="pmid11698530">{{cite journal |vauthors=Sung KW, Choi S, Lovinger DM |title=Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses |journal=Journal of Neurophysiology |volume=86 |issue=5 |pages=2405–12 |date=November 2001 |pmid=11698530 |doi=10.1152/jn.2001.86.5.2405 |s2cid=15299425 }}</ref> although it has largely been replaced by newer drugs such as ]. Its molecular formula is C<sub>21</sub>H<sub>25</sub>NO<sub>4</sub><ref>{{Cite web|url=http://www.chemspider.com/Chemical-Structure.4884363.html|title=LY-307,452 &#124; C21H25NO4 &#124; ChemSpider}}</ref>
	{{pharmacology-stub}}
		⚫	==References==
			{{Reflist|2}}
			{{Metabotropic glutamate receptor modulators}}
⚫	== References ==
	<references/>
		⚫	]
			]
			]
			{{nervous-system-drug-stub}}
	{{Glutamate_receptor_ligands}}
⚫	]